Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BYNeurotherapeutics

Neurological complications of current and emerging CAR-T cell therapies

  • Anna G. Hauswirth1
  • Jorg Dietrich2
  1. 1Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
  2. 2Corresponding author.
Read full textPDFDOICite

Abstract

Harnessing an individual patient's immune system to enhance anti-tumor responses has been a long-standing goal in oncology. Multiple immune modulating or immune enhancing therapies have been FDA approved or are under development, utilizing varying strategies to engage the patient's own immune system. One such therapy is chimeric antigen receptor T-cell therapy (CAR-T), in which T-cells are genetically engineered to target specific antigens present on tumor cells. Multiple CAR-T products are currently approved for clinical use, with impressive and durable responses seen in hematologic cancers. With their efficacy for treating cancer comes the risk of complications, including a high frequency of neurologic complications. Based on the success seen with cellular therapies in hematologic cancers, these technologies are being tested for both the use in solid malignancies, including central nervous system tumors, and for their application in non-neoplastic conditions such as autoimmune diseases. As new CAR-T therapies are designed and introduced into clinical practice, it will be important to assess their risks of neurologic toxicity and to develop therapies to either prevent or treat these complications. Here, we provide an overview of the acute and potentially long-term neurologic complications encountered with these novel and powerful cellular therapies, focusing on emerging CAR-T technologies, their associated neurotoxicities and potential interventions to limit such neurologic complications.

Related

  1. Systemic Therapies in Advanced Adrenocortical Carcinoma: Current Standards, Emerging Strategies, and Practical Considerations
    Lina Pedraza Sanchez, Prerna Dogra, Elio Monsour +1
    CancersPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
  2. Current and emerging therapies in
    Vihang Nakhate, Gilbert Youssef, Patrick Y. Wen
    NeurotherapeuticsPeer-reviewedCC BYFull text4 citedHuman geneticsDOAJ
  3. Emerging cell therapies for gastrointestinal cancers: Advances and future perspectives
    Nobuhiko Kanaya, Shinji Kuroda, Kok-Siong Chen +2
    Molecular Therapy OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  4. Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
    Peng Huang, WenLin Wu, Yu Min +5
    Experimental Hematology & OncologyPeer-reviewedCC BYFull textOncologyDOAJ
  5. Revisiting What HIV in the Brain Can Teach Us About SARS-CoV-2 Neurological Complications
    Layan Taher, Jekzaly Arellano, Lena Al-Harthi
    AIDS research and human retrovirusesPeer-reviewedLicence not statedFull textNeurologyPMC

Cite

BibTeXRIS
BibTeX
@article{hauswirth2026neurological,
  title = {{Neurological complications of current and emerging CAR-T cell therapies}},
  author = {Anna G. Hauswirth and Jorg Dietrich},
  journal = {Neurotherapeutics},
  year = {2026},
  month = oct,
  doi = {10.1016/j.neurot.2026.e00951},
  url = {https://doi.org/10.1016/j.neurot.2026.e00951},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Neurological complications of current and emerging CAR-T cell therapies
AU  - Anna G. Hauswirth
AU  - Jorg Dietrich
PY  - 2026
DA  - 2026/10/24
JO  - Neurotherapeutics
DO  - 10.1016/j.neurot.2026.e00951
UR  - https://doi.org/10.1016/j.neurot.2026.e00951
AB  - Harnessing an individual patient's immune system to enhance anti-tumor responses has been a long-standing goal in oncology. Multiple immune modulating or immune enhancing therapies have been FDA approved or are under development, utilizing varying strategies to engage the patient's own immune system. One such therapy is chimeric antigen receptor T-cell therapy (CAR-T), in which T-cells are genetically engineered to target specific antigens present on tumor cells. Multiple CAR-T products are currently approved for clinical use, with impressive and durable responses seen in hematologic cancers. With their efficacy for treating cancer comes the risk of complications, including a high frequency of neurologic complications. Based on the success seen with cellular therapies in hematologic cancers, these technologies are being tested for both the use in solid malignancies, including central nervous system tumors, and for their application in non-neoplastic conditions such as autoimmune diseases. As new CAR-T therapies are designed and introduced into clinical practice, it will be important to assess their risks of neurologic toxicity and to develop therapies to either prevent or treat these complications. Here, we provide an overview of the acute and potentially long-term neurologic complications encountered with these novel and powerful cellular therapies, focusing on emerging CAR-T technologies, their associated neurotoxicities and potential interventions to limit such neurologic complications.
SN  - 1878-7479
SN  - 1933-7213
ER  -